Characterizing disease burden and progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology 2018; 125: 842–9 CrossRef MEDLINE 10. Heier JS, Lad EM ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

Macular degeneration is a condition that affects the retina, which is neural tissue that lines the back of the eye, like wallpaper in a room. There is an important area ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Signs and symptoms of age-related macular degeneration (AMD) are important to spot to prevent further deterioration of sight.

In response to the TGA's approval of a new drug to treat macular degeneration, UNSW researcher Dr Lisa Nivison-Smith provides context about the ...

Australia's Therapeutic Goods Administration has approved the use of a new and first treatment for geographic atrophy - a disease which causes severe ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...

Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD ...

The company offers year-round educational services on the conditions, using this month, in particular, to guide patients to ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for ...